GC Medical Science Corporation (KOSDAQ:142280)
3,105.00
+5.00 (0.16%)
At close: Sep 11, 2026
GC Medical Science Revenue
GC Medical Science had revenue of 27.11B KRW in the quarter ending June 30, 2026, a decrease of -10.92%. This brings the company's revenue in the last twelve months to 102.16B, down -8.46% year-over-year. In the year 2025, GC Medical Science had annual revenue of 108.41B with 4.39% growth.
Revenue (ttm)
102.16B
Revenue Growth
-8.46%
P/S Ratio
0.73
Revenue / Employee
873.14M
Employees
117
Market Cap
74.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 108.41B | 4.56B | 4.39% |
| Dec 31, 2024 | 103.85B | 9.84B | 10.47% |
| Dec 31, 2023 | 94.01B | -19.10B | -16.88% |
| Dec 31, 2022 | 113.11B | 11.43B | 11.25% |
| Dec 31, 2021 | 101.67B | -11.70B | -10.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Seoulin Bioscience | 83.17B |
| Cytogen | 27.38B |
| Dx & Vx | 26.22B |
| Protia | 17.75B |
| HLB Panagene | 14.71B |
| 3billion | 11.71B |
| GENINUS | 11.28B |
| Median Diagnostics | 7.86B |